mortality/aging
• average survival is 158 days
|
• incomplete penetrance
|
neoplasm
• develop B-lineage leukemia to the same extent as mice expressing the transgene alone
|
• develop B-lineage lymphoma to the same extent as mice expressing the transgene alone
|